I N T E R V I E W
three months have passed since 7 additional adalimumab biosimilars launched in July 2023 , but the biosimilar penetration in this class remains at 2.6 %, based on IQVIA data . Although it is too early to determine the fate of the US adalimumab market , the current dashboard indicates there may be an issue of limited access and limited uptake of lower-cost biosimilar options . So far , the early data is showing that biosimilar uptake is potentially slower when the reference product is in a parity position with biosimilars . Therefore , we need everyone involved in the healthcare space to pay attention to where the market is now and where it is going .
The long-term viability and sustainability of biosimilars is not a guarantee and we need awareness and learnings across therapeutic areas to increase biosimilar utilization . The goal is now and always will be to lower healthcare costs .
Why do you think biosimilar penetration still remains at 2.6 %? Are there specific therapeutic areas where biosimilars are more likely to succeed ?
There are several issues there that could be in play . First , even if PBMs and health plans place these adalimumab biosimilars on their formularies , you still need to have
58
BioVoiceNews | November / December 2023